Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 11 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

This agreement includes milestone payments and profit sharing based on future sales. The partnership aims to enhance patient access to affordable therapies in the healthcare market.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 11, 2023, titled "Zydus andDaewoong Pharmaceutical announce exclusive licensing agreement for development andcommercialization of Leuprolide Long-Acting Injectable in the U.S.".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases